Aerpio Pharmaceuticals Inc (ARPO) Fundamental Analysis & Valuation

NASDAQ:ARPO

Current stock price

2.2
-0.02 (-0.9%)
At close:
2.28
+0.08 (+3.64%)
After Hours:

This ARPO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ARPO Profitability Analysis

1.1 Basic Checks

  • In the past year ARPO has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -49.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ARPO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. ARPO Health Analysis

2.1 Basic Checks

  • There is no outstanding debt for ARPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

  • An Altman-Z score of 22.17 indicates that ARPO is not in any danger for bankruptcy at the moment.
  • There is no outstanding debt for ARPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.17
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

  • A Current Ratio of 16.94 indicates that ARPO has no problem at all paying its short term obligations.
  • A Quick Ratio of 16.94 indicates that ARPO has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ARPO Growth Analysis

3.1 Past

  • The earnings per share for ARPO have decreased strongly by -355.56% in the last year.
  • The Revenue for ARPO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • ARPO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.84% yearly.
  • The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y33.81%
EPS Next 2Y6.46%
EPS Next 3Y34.35%
EPS Next 5Y14.84%
Revenue Next Year-100%
Revenue Next 2Y-56.22%
Revenue Next 3Y-41.69%
Revenue Next 5Y-14.87%

3.3 Evolution

ARPO Yearly Revenue VS EstimatesARPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2022 2023 2024 5M 10M 15M 20M
ARPO Yearly EPS VS EstimatesARPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. ARPO Valuation Analysis

4.1 Price/Earnings Ratio

  • ARPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ARPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARPO Price Earnings VS Forward Price EarningsARPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.12
ARPO Per share dataARPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20 -25

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ARPO's earnings are expected to grow with 34.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y34.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ARPO Dividend Analysis

5.1 Amount

  • No dividends for ARPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ARPO Fundamentals: All Metrics, Ratios and Statistics

Aerpio Pharmaceuticals Inc

NASDAQ:ARPO (8/26/2021, 8:07:55 PM)

After market: 2.28 +0.08 (+3.64%)

2.2

-0.02 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners1.31%
Ins Owner Change0%
Market Cap104.85M
Revenue(TTM)N/A
Net Income(TTM)-18.52M
Analysts100
Price Target47.94 (2079.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.98
P/tB N/A
EV/EBITDA -3.12
EPS(TTM)-0.4
EYN/A
EPS(NY)-27.85
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.74
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.49%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z 22.17
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
EPS Next Y33.81%
EPS Next 2Y6.46%
EPS Next 3Y34.35%
EPS Next 5Y14.84%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-56.22%
Revenue Next 3Y-41.69%
Revenue Next 5Y-14.87%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Aerpio Pharmaceuticals Inc / ARPO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for Aerpio Pharmaceuticals Inc?

ChartMill assigns a fundamental rating of 3 / 10 to ARPO.


Can you provide the valuation status for Aerpio Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 1 / 10 to Aerpio Pharmaceuticals Inc (ARPO). This can be considered as Overvalued.


Can you provide the profitability details for Aerpio Pharmaceuticals Inc?

Aerpio Pharmaceuticals Inc (ARPO) has a profitability rating of 1 / 10.


How financially healthy is Aerpio Pharmaceuticals Inc?

The financial health rating of Aerpio Pharmaceuticals Inc (ARPO) is 8 / 10.


Can you provide the expected EPS growth for ARPO stock?

The Earnings per Share (EPS) of Aerpio Pharmaceuticals Inc (ARPO) is expected to grow by 33.81% in the next year.